구조모아 (StructureMoa)항암 chemical structure spider web
방문Astellas
분석
큐레이션 브리핑
경쟁 포지션: Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
기전. Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CLDN18.2 (claudin-18.2)
CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
US, EU, JP
Approved
vyloy · zolbetuximab · Vyloy · IMAB362 · claudiximab · zolbetuximab-clzb
2026-09-10
Data Confidence · High
Development Signal · Established
Chimeric IgG1 monoclonal antibody
Binds the CLDN18.2 splice variant exposed on tumor cells but buried in normal gastric mucosa
Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality.
구조화 데이터
Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality.
CLDN18.2 heterogeneity and loss under treatment pressure.
Chimeric IgG1 monoclonal antibody
CLDN18.2 (claudin-18.2) · CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining.
Infusion-related nausea and vomiting; hypoalbuminemia monitoring
Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
1L HER2-negative advanced gastric/GEJ adenocarcinoma with CLDN18.2 in ≥75% of tumor cells
1L with fluoropyrimidine and platinum chemotherapy
IV
q2w or q3w aligned to the chemotherapy backbone
Infusion-related nausea and vomiting; hypoalbuminemia monitoring
Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
NK-cell ADCC and complement activation; immunogenic cell death supports chemo synergy.
payload DUO-5, conjugated via site-specific technology
CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining.
CLDN18.2 heterogeneity and loss under treatment pressure.
구조화 데이터
xenograft model
Human
~11 days
PFS/OS in CLDN18.2-high population
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (1L CLDN18.2+ gastric/GEJ)
APPROVAL · 2024년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Astellas
분석
큐레이션 브리핑
경쟁 포지션: Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
기전. Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
CLDN18.2 (claudin-18.2)
CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
US, EU, JP
Approved
vyloy · zolbetuximab · Vyloy · IMAB362 · claudiximab · zolbetuximab-clzb
2026-09-10
Data Confidence · High
Development Signal · Established
Chimeric IgG1 monoclonal antibody
Binds the CLDN18.2 splice variant exposed on tumor cells but buried in normal gastric mucosa
Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality.
구조화 데이터
Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality.
CLDN18.2 heterogeneity and loss under treatment pressure.
Chimeric IgG1 monoclonal antibody
CLDN18.2 (claudin-18.2) · CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining.
Infusion-related nausea and vomiting; hypoalbuminemia monitoring
Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
1L HER2-negative advanced gastric/GEJ adenocarcinoma with CLDN18.2 in ≥75% of tumor cells
1L with fluoropyrimidine and platinum chemotherapy
IV
q2w or q3w aligned to the chemotherapy backbone
Infusion-related nausea and vomiting; hypoalbuminemia monitoring
Only approved CLDN18.2 agent; CAR-T and ADC competitors are still in trials.
Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
NK-cell ADCC and complement activation; immunogenic cell death supports chemo synergy.
payload DUO-5, conjugated via site-specific technology
CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining.
CLDN18.2 heterogeneity and loss under treatment pressure.
구조화 데이터
xenograft model
Human
~11 days
PFS/OS in CLDN18.2-high population
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (1L CLDN18.2+ gastric/GEJ)
APPROVAL · 2024년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.